77 related articles for article (PubMed ID: 18089878)
1. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.
Malempati S; Gaynon PS; Sather H; La MK; Stork LC;
J Clin Oncol; 2007 Dec; 25(36):5800-7. PubMed ID: 18089878
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies.
Matloub Y; Stork L; Asselin B; Hunger SP; Borowitz M; Jones T; Bostrom B; Gastier-Foster JM; Heerema NA; Carroll A; Winick N; Carroll WL; Camitta B; Devidas M; Gaynon PS
Pediatr Blood Cancer; 2016 Feb; 63(2):255-61. PubMed ID: 26485054
[TBL] [Abstract][Full Text] [Related]
3. Poverty and relapse risk in children with acute lymphoblastic leukemia: a Children's Oncology Group study AALL03N1 report.
Wadhwa A; Chen Y; Hageman L; Hoppmann A; Angiolillo A; Dickens DS; Neglia JP; Ravindranath Y; Ritchey AK; Termuhlen A; Wong FL; Landier W; Bhatia S
Blood; 2023 Jul; 142(3):221-229. PubMed ID: 37070673
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous remission of acute lymphoblastic leukemia: A case report.
Höres T; Wendelin K; Schaefer-Eckart K
Oncol Lett; 2018 Jan; 15(1):115-120. PubMed ID: 29285190
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.
Nguyen K; Devidas M; Cheng SC; La M; Raetz EA; Carroll WL; Winick NJ; Hunger SP; Gaynon PS; Loh ML;
Leukemia; 2008 Dec; 22(12):2142-50. PubMed ID: 18818707
[TBL] [Abstract][Full Text] [Related]
6. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience.
Gaynon PS; Qu RP; Chappell RJ; Willoughby ML; Tubergen DG; Steinherz PG; Trigg ME
Cancer; 1998 Apr; 82(7):1387-95. PubMed ID: 9529033
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
Ko RH; Ji L; Barnette P; Bostrom B; Hutchinson R; Raetz E; Seibel NL; Twist CJ; Eckroth E; Sposto R; Gaynon PS; Loh ML
J Clin Oncol; 2010 Feb; 28(4):648-54. PubMed ID: 19841326
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
Reismüller B; Attarbaschi A; Peters C; Dworzak MN; Pötschger U; Urban C; Fink FM; Meister B; Schmitt K; Dieckmann K; Henze G; Haas OA; Gadner H; Mann G;
Br J Haematol; 2009 Feb; 144(4):559-70. PubMed ID: 19077160
[TBL] [Abstract][Full Text] [Related]
11. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
[TBL] [Abstract][Full Text] [Related]
12. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
13. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.
Hogan LE; Meyer JA; Yang J; Wang J; Wong N; Yang W; Condos G; Hunger SP; Raetz E; Saffery R; Relling MV; Bhojwani D; Morrison DJ; Carroll WL
Blood; 2011 Nov; 118(19):5218-26. PubMed ID: 21921043
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an
Feng L; Yao X; Lu X; Wang C; Wang W; Yang J
Abdom Radiol (NY); 2024 Mar; 49(3):888-899. PubMed ID: 38315193
[TBL] [Abstract][Full Text] [Related]
16. Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia.
Ladbury C; Semwal H; Hong D; Yang D; Hao C; Han C; Liu A; Marcucci G; Rosenthal J; Hui S; Salhotra A; Ali H; Nakamura R; Stein A; Al Malki M; Wong JYC; Dandapani S
Front Oncol; 2022; 12():1017355. PubMed ID: 36387179
[TBL] [Abstract][Full Text] [Related]
17. Relapsed Childhood Acute Lymphoblastic Leukemia: Experience from a Single Tertiary Center in Thailand.
Chotsampancharoen T; Songthawee N; Chavananon S; Sripornsawan P; McNeil EB
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3517-3522. PubMed ID: 36308378
[TBL] [Abstract][Full Text] [Related]
18. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Wayne AS; Huynh V; Hijiya N; Rouce RH; Brown PA; Krueger J; Kitko CL; Ziga ED; Hermiston ML; Richards MK; Baruchel A; Schuberth PC; Rossi J; Zhou L; Goyal L; Jain R; Vezan R; Masouleh BK; Lee DW
Haematologica; 2023 Mar; 108(3):747-760. PubMed ID: 36263840
[TBL] [Abstract][Full Text] [Related]
19. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.
Mengxuan S; Fen Z; Runming J
Front Pediatr; 2022; 10():923419. PubMed ID: 35813376
[TBL] [Abstract][Full Text] [Related]
20. Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.
Locatelli F; Zugmaier G; Mergen N; Bader P; Jeha S; Schlegel PG; Bourquin JP; Handgretinger R; Brethon B; Rössig C; Kormany WN; Viswagnachar P; Chen-Santel C
Blood Adv; 2022 Feb; 6(3):1004-1014. PubMed ID: 34979020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
